Opaganib: Difference between revisions

Opaganib
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Latest revision as of 01:11, 20 February 2025

An overview of the investigational drug Opaganib

Opaganib is an investigational drug that is being studied for its potential therapeutic effects in various medical conditions, including cancer and viral infections. It is a small molecule inhibitor that targets specific pathways involved in disease progression.

Mechanism of Action[edit]

Opaganib is known to inhibit the activity of sphingosine kinase-2 (SK2), an enzyme that plays a crucial role in the sphingolipid metabolic pathway. By inhibiting SK2, Opaganib reduces the production of sphingosine-1-phosphate (S1P), a lipid signaling molecule that is involved in cell proliferation, survival, and inflammation. This mechanism is thought to contribute to its potential anti-cancer and anti-inflammatory effects.

Therapeutic Applications[edit]

Cancer[edit]

Opaganib is being investigated for its use in treating various types of cancer, including prostate cancer, breast cancer, and glioblastoma. Its ability to inhibit SK2 and reduce S1P levels may help to slow down tumor growth and enhance the effectiveness of other cancer therapies.

Viral Infections[edit]

Research is also being conducted on the use of Opaganib in treating viral infections, such as COVID-19. The drug's anti-inflammatory properties and its ability to modulate immune responses make it a candidate for reducing the severity of viral infections.

Clinical Trials[edit]

Opaganib is currently undergoing clinical trials to evaluate its safety and efficacy in humans. These trials are essential for determining the appropriate dosing, potential side effects, and overall therapeutic value of the drug.

Side Effects[edit]

As with any investigational drug, Opaganib may have side effects. Commonly reported side effects in clinical trials include gastrointestinal disturbances, fatigue, and headache. The safety profile of Opaganib continues to be evaluated in ongoing studies.

Development and Research[edit]

Opaganib is being developed by RedHill Biopharma, a biopharmaceutical company focused on the development of novel therapeutics. The drug's development is part of a broader effort to explore new treatments for diseases with unmet medical needs.

Related pages[edit]

Opaganib

@@ Line 1: / Line 1: @@
-'''Opaganib''' ([[International Nonproprietary Name|INN]]), also known as ABC-123, is an experimental [[pharmacology|pharmacological]] agent under investigation for various clinical uses, including the treatment of [[inflammatory diseases]], [[cancer]], and [[viral infections]], notably [[COVID-19]]. It is a synthetic [[sphingosine kinase-2]] (SK2) inhibitor, which plays a crucial role in the sphingolipid signaling pathway, influencing cell growth, proliferation, and death. By inhibiting SK2, opaganib aims to modulate these cellular processes, potentially offering therapeutic benefits in conditions where these pathways are dysregulated.
+{{Short description|An overview of the investigational drug Opaganib}}
+{{Drugbox
+| verifiedfields = changed
+| verifiedrevid = 477002123
+| image = Opaganib_structure.png
+| image_size = 200px
+| image_alt = Chemical structure of Opaganib
+| alt = Chemical structure of Opaganib
+}}
+'''Opaganib''' is an investigational drug that is being studied for its potential therapeutic effects in various medical conditions, including [[cancer]] and [[viral infections]]. It is a small molecule inhibitor that targets specific pathways involved in disease progression.
 ==Mechanism of Action==
-Opaganib's mechanism of action involves the inhibition of sphingosine kinase-2 (SK2), an enzyme that catalyzes the formation of [[sphingosine-1-phosphate]] (S1P) from sphingosine. S1P is a bioactive lipid that acts as a critical mediator in various cellular processes, including [[angiogenesis]], [[inflammation]], and [[immune response]]. By reducing S1P levels, opaganib can potentially interfere with the pathological processes of diseases characterized by excessive angiogenesis, inflammation, or aberrant immune activities.
+Opaganib is known to inhibit the activity of [[sphingosine kinase-2]] (SK2), an enzyme that plays a crucial role in the [[sphingolipid]] metabolic pathway. By inhibiting SK2, Opaganib reduces the production of [[sphingosine-1-phosphate]] (S1P), a lipid signaling molecule that is involved in cell proliferation, survival, and inflammation. This mechanism is thought to contribute to its potential anti-cancer and anti-inflammatory effects.
+==Therapeutic Applications==
+===Cancer===
+Opaganib is being investigated for its use in treating various types of cancer, including [[prostate cancer]], [[breast cancer]], and [[glioblastoma]]. Its ability to inhibit SK2 and reduce S1P levels may help to slow down tumor growth and enhance the effectiveness of other cancer therapies.
+===Viral Infections===
+Research is also being conducted on the use of Opaganib in treating viral infections, such as [[COVID-19]]. The drug's anti-inflammatory properties and its ability to modulate immune responses make it a candidate for reducing the severity of viral infections.
 ==Clinical Trials==
-Opaganib has been the subject of multiple clinical trials, exploring its efficacy and safety in different conditions. Notably, its role in treating COVID-19 has garnered significant attention. Early-stage trials have suggested that opaganib may reduce the severity of COVID-19 symptoms and improve outcomes by modulating the body's inflammatory response to the virus. However, comprehensive results from larger, phase III trials are awaited to conclusively determine its effectiveness and safety profile in this context.
+Opaganib is currently undergoing clinical trials to evaluate its safety and efficacy in humans. These trials are essential for determining the appropriate dosing, potential side effects, and overall therapeutic value of the drug.
-In oncology, opaganib is being evaluated for its potential to inhibit tumor growth and metastasis. Its mechanism, which involves the disruption of sphingolipid metabolism—a pathway often dysregulated in cancer cells—provides a novel approach to cancer therapy. Clinical trials in this area are ongoing, with the aim of establishing opaganib's efficacy as a monotherapy or in combination with other anticancer agents.
-==Safety and Tolerability==
+==Side Effects==
-The safety profile of opaganib is currently under investigation in various clinical trials. Preliminary data suggest that it is generally well-tolerated, with the most common adverse effects being mild to moderate in severity. However, as with any experimental therapy, a thorough assessment of its safety, particularly in long-term use, is essential.
+As with any investigational drug, Opaganib may have side effects. Commonly reported side effects in clinical trials include gastrointestinal disturbances, fatigue, and headache. The safety profile of Opaganib continues to be evaluated in ongoing studies.
-==Regulatory Status==
+==Development and Research==
-As of the last update, opaganib remains an investigational drug and has not received approval from any regulatory body, including the [[United States Food and Drug Administration|U.S. Food and Drug Administration]] (FDA) or the [[European Medicines Agency]] (EMA). Its development and clinical trials are being closely monitored to ensure compliance with regulatory standards and to determine its future in medical treatment.
+Opaganib is being developed by [[RedHill Biopharma]], a biopharmaceutical company focused on the development of novel therapeutics. The drug's development is part of a broader effort to explore new treatments for diseases with unmet medical needs.
-==Conclusion==
+==Related pages==
-Opaganib represents a promising avenue in the treatment of diseases with underlying mechanisms related to sphingolipid signaling, such as cancer, inflammatory conditions, and viral infections like COVID-19. While early clinical trials offer encouraging data, the scientific and medical communities await the results of ongoing and future studies to fully understand its therapeutic potential and safety profile.
+* [[Sphingosine kinase]]
+* [[Sphingolipid metabolism]]
+* [[Cancer treatment]]
+* [[Antiviral drugs]]
-[[Category:Experimental drugs]]
+[[Category:Investigational drugs]]
-[[Category:COVID-19 drug research]]
+[[Category:Anticancer drugs]]
-[[Category:Oncology]]
+[[Category:Antiviral drugs]]
-{{medicine-stub}}
+<gallery>
+File:Opaganib structure.png|Opaganib
+</gallery>